CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
CervoMed announced PK, regulatory, and manufacturing advances enabling a higher-dose, twice-daily oral regimen of neflamapimod, its lead drug candidate for age-related brain disorders. The FDA removed the prior plasma drug exposure limit after a 39-week dog toxicology study established a NOAEL more than 30-fold above the clinically active exposure range, and a new 50 mg tablet showed a PK profile suited to BID dosing, with roughly 20% lower peak and 20% higher 12-hour trough concentrations versus the prior capsule.
Key figures
- Drug Name
- neflamapimod
- New formulation
- 50 mg oral tablet
- Planned regimen
- 100 mg twice daily (BID)
- Cmax change vs capsule
- approximately 20% lower
- Ctrough change vs capsule
- approximately 20% higher
- Trough increase vs 40mg TID
- approximately 33%
- Dog tox noeal margin vs active range
- more than 30-fold higher
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.